Cat. No.: HY-N0716

Berberine

(Synonyms: Natural Yellow 18)

81 Cited Publications

Customer Review

Based on 81 publication(s) in Google Scholar

Berberine (Natural Yellow 18) is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine (Natural Yellow 18) induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine (Natural Yellow 18) has antineoplastic properties. The sulfate form (HY-N0716B) improves bioavailability.

For research use only. We do not sell to patients.

CAS No.: 2086-83-1
Formula: C₂₀H₁₈NO₄⁺
Molecular Weight:336.36

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (281 KB)

Berberine Chemical Structure

CAS No.: 2086-83-1

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (81)
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

ROS^[1]
DNA topoisomerase^[1]

All Antibiotic Isoforms :

All Topoisomerase Isoforms :

All Parasite Isoforms :

All PI3K Isoforms :

All Akt Isoforms :

All Caspase Isoforms :

All JNK Isoforms :

All AP-1 Isoforms :

All NF-κB Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	21.84 μM Compound: Berberine	Cytotoxicity against mouse 3T3L1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Cytotoxicity against mouse 3T3L1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 28818460]
A2780/Taxol	IC₅₀	>=24.33 μM Compound: 2	Antiproliferative activity against human A2780T cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human A2780T cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 39213483]
A549/TR	IC₅₀	>=24.33 μM Compound: 2	Antiproliferative activity against human A549/Taxol cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human A549/Taxol cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 39213483]
BHK-21	CC₅₀	>100 μM Compound: 190	Cytotoxicity against BHK21 cells in presence of ATP by Celltiter-Glo assay Cytotoxicity against BHK21 cells in presence of ATP by Celltiter-Glo assay	[PMID: 28689975]
CWR22R	IC₅₀	12.7 μM Compound: 51	Antiproliferative activity against human 22Rv1 cells Antiproliferative activity against human 22Rv1 cells	[PMID: 36459083]
HeLa	IC₅₀	12.08 μg/mL Compound: Berberine	Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay	[PMID: 31821990]
HeLa 229	IC₅₀	42.93 μM Compound: Berberine	Cytotoxicity against human HeLa 229 cells measured after 48 hrs by MTT assay Cytotoxicity against human HeLa 229 cells measured after 48 hrs by MTT assay	[PMID: 31821990]
Hep 3B2	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
HepG2	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against cisplatin-resistant human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against cisplatin-resistant human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
HepG2	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
HepG2	IC₅₀	2.5 μM Compound: 24	Inhibition of CYP1B1 in human HepG2 cells Inhibition of CYP1B1 in human HepG2 cells	[PMID: 30503941]
HepG2	IC₅₀	46.9 μg/mL Compound: 1; BBR	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27561717]
Huh-7	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
HUVEC	IC₅₀	18.34 μM Compound: Berberine	Cytotoxicity against human HUVEC cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HUVEC cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
LNCaP	IC₅₀	3.4 μM Compound: 51	Antiproliferative activity against human LNCap cells Antiproliferative activity against human LNCap cells	[PMID: 36459083]
LNCaP C4-2B	IC₅₀	11.2 μM Compound: 51	Antiproliferative activity against human LNCaP C4-2B cells Antiproliferative activity against human LNCaP C4-2B cells	[PMID: 36459083]
LoVo	IC₅₀	>=24.33 μM Compound: 2	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 39213483]
LX-2	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human LX2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human LX2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
MDCK	CC₅₀	70.22 μg/mL Compound: Ber	Cytotoxicity against MDCK cells incubated for 48 hrs assessed as reduction in cell viability by SRB assay Cytotoxicity against MDCK cells incubated for 48 hrs assessed as reduction in cell viability by SRB assay	[PMID: 28958846]
PC-3	IC₅₀	>=24.33 μM Compound: 2	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 39213483]
PC-3	IC₅₀	21.5 μM Compound: 51	Antiproliferative activity against human PC-3 cells Antiproliferative activity against human PC-3 cells	[PMID: 36459083]
RAW264.7	IC₅₀	>30 μM Compound: 6	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay	[PMID: 22024033]
RAW264.7	IC₅₀	6.9 μM Compound: Berberine	Inhibition of PCSK9 mRNA level in mouse RAW264.7 cells by qRT-PCR assay Inhibition of PCSK9 mRNA level in mouse RAW264.7 cells by qRT-PCR assay	[PMID: 30698432]
SK-HEP1	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36640595]
SMMC-7721	IC₅₀	18.34 μM Compound: Berberine	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SW1990	IC₅₀	18.34 μM Compound: Berberine	Cytotoxicity against human SW1990 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SW1990 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
Vero	IC₅₀	71.14 μg/mL Compound: Berberine	Cytotoxicity against African green monkey Vero cells measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells measured after 48 hrs by MTT assay	[PMID: 31821990]
Vero C1008	CC₅₀	221 μM Compound: 49	Cytotoxicity against African green monkey Vero E6 cells measured up to 24 to 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells measured up to 24 to 72 hrs by MTT assay	[PMID: 31549836]
Vero C1008	IC₅₀	39.1 μM Compound: 49	Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in virus infectivity preincubated with virus for 1 hr followed by cell infection and measured after 96 hrs by crystal violet staining based assay Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in virus infectivity preincubated with virus for 1 hr followed by cell infection and measured after 96 hrs by crystal violet staining based assay	[PMID: 31549836]

In Vitro

Berberine (1.25-160 μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29^[1].
Berberine (1.25-160 μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth^[1].
LoVo cells are exposure to Berberine (10-80 μM) for 24 h. Cell cycle analysis of 40 μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase^[1].
Berberine (10-80 μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0 μM^[1].
Berberine exhibits antimicrobial acitivity through inhibition of cell division protein FtsZ, or through DNA/RNA binding and deal thus DNA/RNAdamege^[3].
Berberine exhibts anti-inflammatory activity by inhibiting TNF-α and the activation of its downstream pathway AP-1 and NF-kB^[4].
Berberine exhibits neuroprotective efficacy by inhibiting the reactive oxygen species (ROS) production and caspase activation, and activatiing the PI3K/Akt signaling pathway, and heme oxygenase-1 (HO-1) expression^[5].
Berberine attenuates metabolic diseases through regulations of the lipids composition and inhibition of insulin resistance^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29
Concentration:

1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM
Incubation Time:

72 hours
Result:

Inhibited the proliferation of four cell lines. The IC₅₀ ranged from 40.8±4.1 μM (LoVo) to 98.6±2.9 μM (HCT116).

Cell Proliferation Assay^[1]

Cell Line:

Colorectal carcinoma cell lines LoVo
Concentration:

1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM
Incubation Time:

24, 48, 72 hours
Result:

Induced a time- and dose-dependent inhibition of cell growth. By 72 h, 160.0 μM induced 71.1±1.9 % growth inhibitions in LoVo cells.

Cell Cycle Analysis^[1]

Cell Line:

LoVo cells
Concentration:

0, 10, 20, 40, or 80 μM
Incubation Time:

24 hours
Result:

Exposure to 40.0 μM induced G2/M-phase cell cycle arrest, an increase in the G2/M-phase population and a progressive decline in the G1 population.

Western Blot Analysis^[1]

Cell Line:

LoVo cells
Concentration:

10, 20, 40, or 80 μM
Incubation Time:

24 hours
Result:

Suppressed cyclin B1, cdc2 and cdc25c protein expression.

In Vivo

Berberine (10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine at doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

5-week-old BALB/c nu/nu mice with human colorectal adenocarcinoma LoVo xenografts^[1]
Dosage:

10, 30, or 50 mg/kg/day
Administration:

Gastrointestinal gavage; for 10 consecutive days
Result:

Showed inhibitory rates of 33.1 % and 45.3 % at doses of 30 and 50 mg/kg/day.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 2086-83-1
Molecular Weight 336.36
Formula C₂₀H₁₈NO₄⁺
SMILES

COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1
Synonyms

Natural Yellow 18
Structure Classification
- Alkaloids
- Isoquinoline Alkaloids
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (81)

All In Vivo Efficacy StudyBio/Physico-chemical AssayRT-PCRIFOthersWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cell Stem Cell

Vagal pathway activation links chronic stress to decline in intestinal stem cell function. [Abstract]

2025 Mar 20:S1934-5909(25)00084-0. PMID: 40120585
Nat Commun

Mitochondrial-cytochrome c oxidase II promotes glutaminolysis to sustain tumor cell survival upon glucose deprivation. [Abstract]

2025 Jan 2;16(1):212. PMID: 39747079

Berberine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):212. [Abstract]

A549 (1 ×10⁶) cells were subcutaneously inoculated into the right scruff of the female BALB/c nude mouse (n = 8/group). On day 22 after inoculation, mice were given Berberine (p.o.; 40 mg/kg; daily for 12 days) . The tumor volumes on indicated days after gavage were examined

Berberine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):212. [Abstract]

H1299 cells were treated with or without Berberine (Ber;5 μM; 24 h). Cells were subjected to qPCR (n = 3 independent experiments) analyses.
Acta Pharm Sin B

Palmitoylated SARM1 targeting P4HA1 promotes collagen deposition and myocardial fibrosis: A new target for anti-myocardial fibrosis. [Abstract]

2025 Sep;15(9):4789-4806. PMID: 41049740

Berberine purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]

The hydroxyproline assay kit was used to detect the secretion of fibroblast collagen in NMCFs by Berberine (BBC; 70 μM）. n=3-4. *P< 0.05, **P< 0.01 vs. CTL #P<0.05, ###P <0.001 vs. TGF-β1.

Berberine purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]

Immunofluorescence in determining the expression of P4HA1 after treated with Berberine (BBC; p.o.; 20 mg/kg for 7 days ) and Selonsertib (p.o.; 20 mg/kg for 7 days ) in the heart tissue of MI mice. n=3. *P < 0.05, **P < 0.01 vs. Sham, #P < 0.05, ##P < 0.01 vs. MI. Scale bar, 200 µm.

Berberine purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]

Echocardiographic detection of cardiac function changes in MI mice and treated with Berberine (BBC; p.o.; 20 mg/kg for 7 days ) and Selonsertib (p.o.; 20 mg/kg for 7 days ) . n=3-4. *P < 0.05 vs. Sham, #P < 0.05 vs. MI.
Adv Sci (Weinh)

ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. [Abstract]

2026 Mar;13(16):e13310. PMID: 41589654
J Hazard Mater

Ammonia-induced exosomal miRNA disrupts autophagy and promotes lung injury: Therapeutic potential of natural compounds. [Abstract]

2026 Mar 15:506:141417. PMID: 41775203
NPJ Biofilms Microbiomes

Berberine chloride hydrate impairs Streptococcus mutans biofilm formation via inhibiting sortase A activity. [Abstract]

2025 Jul 1;11(1):120. PMID: 40595693
Int J Biol Macromol

Berberine@AgNPs@Carboxylated chitosan hydrogel dressing with immunomodulatory and anti-biofilm properties promotes wound repair in drug-resistant bacterial infections. [Abstract]

2025 May 21:144496. PMID: 40409636
Acta Pharmacol Sin

Tetrahydroberberrubine retards heart aging in mice by promoting PHB2-mediated mitophagy. [Abstract]

2023 Feb;44(2):332-344. PMID: 35948750
Phytomedicine

Berberine facilitates alveolar bone regeneration via Ptgs2-mediated dual regulation of osteoblast differentiation and fibroblast inhibition. [Abstract]

2025 Dec 7:150:157678. PMID: 41401587
Phytomedicine

Huang-Lian-Jie-Du decoction enhances Capecitabine-Oxaliplatin efficacy via Akkermansia muciniphila and CD8+ T cells in colorectal cancer. [Abstract]

2025 Sep 4:148:157233. PMID: 40972261
Phytomedicine

Berberine protects against dysentery by targeting both Shigella filamentous temperature sensitive protein Z and host pyroptosis: Resolving in vitro-vivo effect discrepancy. [Abstract]

2025 Apr:139:156517. PMID: 39986228
Phytomedicine

Swiprosin-1 participates in the berberine-regulated AMPK/MLCK pathway to attenuate colitis-induced tight junction damage. [Abstract]

2024 Dec:135:156111. PMID: 39369569
Phytomedicine

Modified Hu-lu-ba-wan protects diabetic glomerular podocytes via promoting PKM2-mediated mitochondrial dynamic homeostasis. [Abstract]

2024 Jan:123:155247. PMID: 38128393
Phytomedicine

Berberine ameliorates iron levels and ferroptosis in the brain of 3 × Tg-AD mice. [Abstract]

2023 Sep:118:154962. PMID: 37506403
Free Radic Biol Med

Redox switch C674 in SERCA2 triggers Ca2+-calcineurin-MCU-Drp1 cascade and pulmonary vascular remodeling. [Abstract]

2025 Dec 16:244:380-394. PMID: 41412527
NPJ Sci Food

Network pharmacology study on the mechanism of berberine in Alzheimer's disease model. [Abstract]

2025 Feb 4;9(1):16. PMID: 39900946
Biomed Pharmacother

Berberine exerts antidepressant effects in vivo and in vitro through the PI3K/AKT/CREB/BDNF signaling pathway. [Abstract]

2024 Jan:170:116012. PMID: 38113631
Int J Nanomedicine

Combined Therapy of Experimental Autoimmune Uveitis by a Dual-Drug Nanocomposite Formulation with Berberine and Dexamethasone. [Abstract]

2023 Jul 31:18:4347-4363. PMID: 37545873
Mol Med

Berberine promotes primordial follicle activation and increases ovulated oocyte quantity in aged mice. [Abstract]

2024 Dec 20;30(1):251. PMID: 39707173
Dent Mater

Injectable, regenerative and anti-infective PEGylated polyglycerol sebacate-modified calcium phosphate cements triggered by berberine and rhBMP-2 for oral bone defect repair. [Abstract]

2026 May;42(5):898-911. PMID: 41633879
Phytother Res

A Novel Mechanism of Berberine Targeting EIF2AK2 Dimerization Attenuates Methylglyoxal-Induced Endothelial Senescence and Apoptosis. [Abstract]

2026 Mar;40(3):887-906. PMID: 41520368
JCI Insight

Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment. [Abstract]

2023 Jul 24;8(14):e166306. PMID: 37485875
Chin Med

Berberine ameliorates high-fat diet-induced metabolic disorders through promoting gut Akkermansia and modulating bile acid metabolism. [Abstract]

2025 Nov 17;20(1):190. PMID: 41243097
Biochem Pharmacol

Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis. [Abstract]

2021 Jun:188:114576. PMID: 33930347
J Ethnopharmacol

Jiao-tai-wan and its effective component-berberine improve diabetes and depressive disorder through the cAMP/PKA/CREB signaling pathway. [Abstract]

2024 Apr 24:324:117829. PMID: 38296172
J Ethnopharmacol

Exploring the pathogenesis of type 2 diabetes mellitus intestinal damp-heat syndrome and the therapeutic effect of Gegen Qinlian Decoction from the perspective of exosomal miRNA. [Abstract]

2022 Mar 1:285:114786. PMID: 34763043
Inflammopharmacology

Berberine mitigates diclofenac-induced intestinal mucosal mechanical barrier dysfunction through the restoration of autophagy by inhibiting exosome-mediated lncRNA H19. [Abstract]

2024 May 17. PMID: 38758516
Mech Ageing Dev

AMPK alleviates oxidative stress‑induced premature senescence via inhibition of NF-κB/STAT3 axis-mediated positive feedback loop. [Abstract]

2020 Oct;191:111347. PMID: 32882228
CNS Neurosci Ther

Berberine Alleviates Kainic Acid-Induced Acute Epileptic Seizures in Mice via Reshaping Gut Microbiota-Associated Lipid Metabolism. [Abstract]

2025 Feb;31(2):e70253. PMID: 39915895
Int J Mol Sci

Berberine Alleviates Shigella-Induced Dysentery by Regulating Intestinal Barrier and Inflammatory Responses. [Abstract]

2026 Jan 21;27(2):1063. PMID: 41596706
Front Pharmacol

Berberine stimulates lysosomal AMPK independent of PEN2 and maintains cellular AMPK activity through inhibiting the dephosphorylation regulator UHRF1. [Abstract]

2023 Apr 18:14:1148611. PMID: 37144221
Pharm Biol

Berberine decreases S100B generation to regulate gut vascular barrier permeability in mice with burn injury. [Abstract]

2024 Dec;62(1):53-61. PMID: 38108311
Int Immunopharmacol

Berberine attenuates neuronal ferroptosis via the AMPK-NRF2-HO-1-signaling pathway in spinal cord-injured rats. [Abstract]

2024 Sep 24;142(Pt B):113227. PMID: 39321704
Int Immunopharmacol

Berberine enhances the function of intestinal stem cells in healthy and radiation-injured mice. [Abstract]

2024 May 29:136:112278. PMID: 38815353
Int Immunopharmacol

Berberine alleviates neuroinflammation by downregulating NFκB/LCN2 pathway in sepsis-associated encephalopathy: network pharmacology, bioinformatics, and experimental validation. [Abstract]

2024 May 30:133:112036. PMID: 38640713
Molecules

Discovery of Nine Dipeptidyl Peptidase-4 Inhibitors from Coptis chinensis Using Virtual Screening, Bioactivity Evaluation, and Binding Studies. [Abstract]

2024 May 14;29(10):2304. PMID: 38792165
Hepatol Commun

Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway. [Abstract]

2024 Mar 29;8(4):e0405. PMID: 38573832
Drug Dev Res

Polydatin Protects Against the Formation of PPE-Induced Abdominal Aortic Aneurysms in Mice by Activating Nuclear Factor Erythroid 2-Related Factor 2. [Abstract]

2026 Feb;87(1):e70223. PMID: 41486502
J Cell Mol Med

Berberine Sensitises Breast Cancer Cells to Radiation via the Attenuation of DNA Ligase III. [Abstract]

2025 Sep;29(17):e70836. PMID: 40916080
J Food Biochem

2025 Jul 16.
Biochim Biophys Acta Mol Basis Dis

Berberine chloride alleviated intestinal inflammation and improved postoperative ileus by regulating macrophage polarization via PI3K/AKT signaling pathway. [Abstract]

2025 May 22:167920. PMID: 40412730
J Inflamm Res

Berberine Inhibits Acne-Related Lipid Secretion and Inflammation by Regulating the hsa-miR-3150a-3p/TP53 Pathway. [Abstract]

2025 Aug 21:18:11451-11461. PMID: 40860941
Sci Rep

Ursolic and oleanolic acids suppress MNNG induced malignant transformation of human gastric mucosal epithelium by regulating the PI3 K/AKT pathway. [Abstract]

2025 Jul 1;15(1):21623. PMID: 40594240
Fish Shellfish Immunol

Berberine inhibits SGIV replication by suppressing inflammatory response and oxidative stress. [Abstract]

2024 Jun:149:109522. PMID: 38548190
Sci Rep

Enhanced CHOLESTEROL biosynthesis promotes breast cancer metastasis via modulating CCDC25 expression and neutrophil extracellular traps formation. [Abstract]

2022 Oct 17;12(1):17350. PMID: 36253427
Aquacult Nutr

14 Jul 2022.
Aquaculture

15 May 2022, 738055.
Microbiol Spectr

The inhibitory effect of berberine chloride hydrate on Streptococcus mutans biofilm formation at different pH values. [Abstract]

2023 Sep 25;11(5):e0217023. PMID: 37747238
Cell Signal

Inhibition of N6-methyladenosine methylation of ASC by berberine ameliorates pyroptosis of renal tubular epithelial cells in acute kidney injury. [Abstract]

2025 Jul:131:111732. PMID: 40074191
Microb Pathog

Berberine inhibits Mycoplasma synoviae infection by suppressing PIK3CA-dependent inflammatory and apoptotic responses in avian macrophages. [Abstract]

2025 Dec:209:108114. PMID: 41115537
Exp Cell Res

Berberine increases the killing effect of pirarubicin on HCC cells by inhibiting ATG4B-autophagy pathway. [Abstract]

2024 May 13:114094. PMID: 38750718
Food Chem Toxicol

Berberine attenuates sunitinib-induced cardiac dysfunction by normalizing calcium regulation disorder via SGK1 activation. [Abstract]

2023 May:175:113743. PMID: 36972840
Mol Med Rep

Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. [Abstract]

2023 Jan;27(1):17. PMID: 36453238
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Toxicol Appl Pharmacol

Berberine alleviates acute embolism-induced lung inflammation and injury by suppressing miR-22-5p expression and modulating the TLR4/NF-κB signaling pathway. [Abstract]

2025 Sep 13:505:117563. PMID: 40953642
Appl Biochem Biotechnol

Berberine Protects Against Dihydrotestosterone-Induced Human Ovarian Granulosa Cell Injury and Ferroptosis by Regulating the Circ_0097636/MiR-186-5p/SIRT3 Pathway. [Abstract]

2024 Aug;196(8):5265-5282. PMID: 38153651
J Pharm Pharmacol

Berberine suppresses the migration and invasion of colon cancer cells by inhibition of lipogenesis through modulation of promyelocytic leukemia zinc finger-mediated sterol-regulatory element binding proteins cleavage-activating protein ubiquitination. [Abstract]

2022 Sep 1;74(9):1353-1363. PMID: 35641094
J Appl Microbiol

Enhanced in vitro antimicrobial activity of amphotericin B with berberine against dual-species biofilms of Candida albicans and Staphylococcus aureus. [Abstract]

2021 Apr;130(4):1154-1172. PMID: 32996236
Cardiovasc Drugs Ther

Berberine Reverses Nitroglycerin Tolerance through Suppressing Protein Kinase C Alpha Activity in Vascular Smooth Muscle Cells. [Abstract]

2022 Aug;36(4):633-643. PMID: 34319490
Mol Reprod Dev

Effect of berberine combined with metformin on autophagy in polycystic ovary syndrome by regulating AMPK/AKT/mTOR pathway. [Abstract]

2024 Aug;91(8):e23768. PMID: 39155689
J Appl Toxicol

Berberine prevents against myocardial injury induced by acute β-adrenergic overactivation in rats. [Abstract]

2024 Nov;44(11):1700-1713. PMID: 38981847
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Toxicol In Vitro

Inhibitory potential of phytochemicals on species-specific breast cancer resistance protein transport activity. [Abstract]

2025 Dec:109:106128. PMID: 40796067
BMC Pharmacol Toxicol

Antitumor effects of erlotinib in combination with berberine in A431 cells. [Abstract]

2023 May 11;24(1):29. PMID: 37170144

Berberine purchased from MedChemExpress. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]

Berberine (BBR; 2.5, 5, 10 µM; 48 h) inhibits EGFR phosphorylation in a dose-dependent matter in A431cells.

Berberine purchased from MedChemExpress. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]

Berberine (BBR; 2.5 µM; 10 days) significantly inhibits NCI-H441 colony formation.

Berberine purchased from MedChemExpress. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]

Berberine (BBR; 0.625, 1.25, 2.5, 5, 10 µM; 48 h) inhibits the viability of A431cells in a dose-dependent matter.
Tissue Cell

Overcoming osimertinib resistance in NSCLC: The role of Notch1 pathway inhibition by berberine. [Abstract]

2026 Jun:100:103365. PMID: 41687187
Oncologie

2023 Mar 10.
Gene

Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress. [Abstract]

2022 Mar 30:816:146171. PMID: 35026293
Oncol Lett

Genome-wide CRISPR screening identifies CLDN1 as a central node in the anticancer mechanisms of berberine and as a therapeutic target in lung cancer. [Abstract]

2025 Dec 1;31(2):62. PMID: 41383979
J Bone Miner Metab

Protective effects of berberine on senile osteoporosis in mice. [Abstract]

2021 Sep;39(5):748-756. PMID: 33829324
Arch Oral Biol

Investigating the mechanism of berberine in inhibiting periodontitis progression using machine learning, molecular docking, and experimental validation. [Abstract]

2026 Mar:183:106496. PMID: 41544413
Biol Pharm Bull

Berberine Encapsulated in Exosomes Derived from Platelet-Rich Plasma Promotes Chondrogenic Differentiation of the Bone Marrow Mesenchymal Stem Cells via the Wnt/β-Catenin Pathway. [Abstract]

2022 Oct 1;45(10):1444-1451. PMID: 35858798
Lett Drug Des Discov

2025 Dec 13.
bioRxiv

Mechanistic Language Modeling and Oxygenated 3D Screening Reveal Berberine and Enzalutamide Synergy in Resistant Prostate Cancer. [Abstract]

2026 Jan 26:2026.01.24.701539. PMID: 41659618
Res Sq

2025 Apr 15.
Genome Instab Dis

2025 Mar.
SSRN

2023 Jan 27.
Research Square Print

2022 Aug.
Research Square Preprint

2021 Sep.
Research Square Preprint

2021 Jun.
Research Square Preprint

2021 May.
Evid Based Complement Alternat Med

Effects of Berberine on Circular RNA Expression Profiles in Human Gastric Cancer Cells. [Abstract]

2021 May 4:2021:6688629. PMID: 34055022

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Cai Y, et al. Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J Nat Med. 2014 Jan;68(1):53-62. [Content Brief]

[2]. Cui HX, et al. Preparation and Evaluation of Antidiabetic Agents of Berberine Organic Acid Salts for Enhancing the Bioavailability. Molecules. 2018 Dec 28;24(1):103. [Content Brief]

[3]. Boberek JM, et al., Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS One. 2010 Oct 29;5(10):e13745. [Content Brief]

[4]. Remppis A, et al., Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway. Mediators Inflamm. 2010;2010:194896. [Content Brief]

[5]. Bae J, et al., Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1. Mol Cells. 2013 Feb;35(2):151-7. [Content Brief]

[6]. Ye Y, et al., Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2021 Apr 26;12:653887. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Berberine

Publications Citing Use of MedChemExpress (MCE) Berberine

All Antibiotic Isoforms

All Topoisomerase Isoforms

All Parasite Isoforms

All PI3K Isoforms

All Akt Isoforms

All Caspase Isoforms

All JNK Isoforms

All AP-1 Isoforms

All NF-κB Isoforms